Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.
The prospective registry shall provide new insights into muscular involvement associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For that reason consecutive patients with proven corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital, are enrolled. Multimodal assessment of neuromuscular pathology is based on medical history, laboratory biomarkers including inflammation parameters and autoimmune antibodies, vital parameters monitoring, muscle ultrasound, transthoracic echocardiography, electroneurography, as well as electromyography. Inclusion of follow-up visits permit longitudinal and prognostic evaluation of diagnostic and therapeutic interventions (e.g. immunomodulation with immunoglobulins, corticosteroids, or interleukin 6 receptor antagonists).
Study Type
OBSERVATIONAL
Enrollment
500
creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
University Hospital Tuebingen
Tübingen, Germany
RECRUITINGRate of elevated creatine kinase in hyperacute phase
Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)
Time frame: 1 week
Rate of elevated creatine kinase
Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Time frame: 24 months
Rate of two-peak elevation of creatine kinase during acute phase
Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)
Time frame: 30 days
Rate of myositis-specific antibodies
Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up
Time frame: 24 months
Rate of antimyocardial antibodies
Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up
Time frame: 24 months
Area under the curve (AUC) of elevated creatine kinase
Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)
Time frame: 24 months
Peak-levels of elevated creatine kinase
Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Time frame: 24 months
Peak-levels of troponin
Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)
Time frame: 30 days
Peak-levels of urine myoglobin
Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)
Time frame: 30 days
Rate of muscle hyperechogenicity
Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Time frame: 24 months
Peak-muscle hyperechogenicity
Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.